Armoring CRAds with p21/Waf-1 shRNAs

The next generation of oncolytic adenoviruses

N. Höti, W. H. Chowdhury, S. Mustafa, J. Ribas, M. Castanares, T. Johnson, M. Liu, Shawn Lupold, R. Rodriguez

Research output: Contribution to journalArticle

Abstract

Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.

Original languageEnglish (US)
Pages (from-to)585-597
Number of pages13
JournalCancer Gene Therapy
Volume17
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Adenoviridae
RNA Interference
Small Interfering RNA
Prostatic Neoplasms
Neoplasms
Oncolytic Viruses
Cyclin-Dependent Kinase Inhibitor p21
Viruses
Viral Genes
Life Cycle Stages
Doxorubicin
Androgens
Prostate
Technology
Growth
Genes
Therapeutics

Keywords

  • Adenovirus
  • CRAd
  • P21/Waf-1
  • Prostate cancer
  • ShRNA

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology
  • Medicine(all)

Cite this

Höti, N., Chowdhury, W. H., Mustafa, S., Ribas, J., Castanares, M., Johnson, T., ... Rodriguez, R. (2010). Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses. Cancer Gene Therapy, 17(8), 585-597. https://doi.org/10.1038/cgt.2010.15

Armoring CRAds with p21/Waf-1 shRNAs : The next generation of oncolytic adenoviruses. / Höti, N.; Chowdhury, W. H.; Mustafa, S.; Ribas, J.; Castanares, M.; Johnson, T.; Liu, M.; Lupold, Shawn; Rodriguez, R.

In: Cancer Gene Therapy, Vol. 17, No. 8, 08.2010, p. 585-597.

Research output: Contribution to journalArticle

Höti, N, Chowdhury, WH, Mustafa, S, Ribas, J, Castanares, M, Johnson, T, Liu, M, Lupold, S & Rodriguez, R 2010, 'Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses', Cancer Gene Therapy, vol. 17, no. 8, pp. 585-597. https://doi.org/10.1038/cgt.2010.15
Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T et al. Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses. Cancer Gene Therapy. 2010 Aug;17(8):585-597. https://doi.org/10.1038/cgt.2010.15
Höti, N. ; Chowdhury, W. H. ; Mustafa, S. ; Ribas, J. ; Castanares, M. ; Johnson, T. ; Liu, M. ; Lupold, Shawn ; Rodriguez, R. / Armoring CRAds with p21/Waf-1 shRNAs : The next generation of oncolytic adenoviruses. In: Cancer Gene Therapy. 2010 ; Vol. 17, No. 8. pp. 585-597.
@article{e0273c623e664f978ff074529589139c,
title = "Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses",
abstract = "Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.",
keywords = "Adenovirus, CRAd, P21/Waf-1, Prostate cancer, ShRNA",
author = "N. H{\"o}ti and Chowdhury, {W. H.} and S. Mustafa and J. Ribas and M. Castanares and T. Johnson and M. Liu and Shawn Lupold and R. Rodriguez",
year = "2010",
month = "8",
doi = "10.1038/cgt.2010.15",
language = "English (US)",
volume = "17",
pages = "585--597",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Armoring CRAds with p21/Waf-1 shRNAs

T2 - The next generation of oncolytic adenoviruses

AU - Höti, N.

AU - Chowdhury, W. H.

AU - Mustafa, S.

AU - Ribas, J.

AU - Castanares, M.

AU - Johnson, T.

AU - Liu, M.

AU - Lupold, Shawn

AU - Rodriguez, R.

PY - 2010/8

Y1 - 2010/8

N2 - Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.

AB - Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.

KW - Adenovirus

KW - CRAd

KW - P21/Waf-1

KW - Prostate cancer

KW - ShRNA

UR - http://www.scopus.com/inward/record.url?scp=77954816343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954816343&partnerID=8YFLogxK

U2 - 10.1038/cgt.2010.15

DO - 10.1038/cgt.2010.15

M3 - Article

VL - 17

SP - 585

EP - 597

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -